Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001506983 0001506983 2026-08-07 2026-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
How this was made
The 30-second read
Why it matters
The amendment changes the share issuance schedule and introduces a true-up payment obligation if the commitment fee price is below a minimum price, potentially increasing investor compensation and dilution expectations.
Market read
This is a direct capital-structure update that can affect near-term valuation via dilution expectations and financing overhang, especially for microcaps.
What to watch
Traders should check the ELOC agreement’s Minimum Price and Commitment Fee Price definitions and whether the resale registration statement is already effective or imminent, since that determines how soon dilution could occur.
Background
Glucotrack entered an ELOC purchase agreement on July 14, 2026 with White Lion Capital, and this 8-K reports Amendment No. 1 dated Aug 7, 2026.
Ticker impact
Glucotrack amended its ELOC with White Lion Capital to issue 2,505,513 shares after a resale registration statement becomes effective.
Likely modest negative to neutral bias as ELOC share issuance and true-up risk can pressure dilution expectations, especially if the minimum price is at risk.
The filing is a fresh, company-specific capital-structure update (8-K Item 1.01) with explicit share count and a defined true-up condition, but it does not disclose proceeds, timing beyond registration effectiveness, or a definitive cash amount beyond the $1.0M fee framework.
Market effects
Adds another example of ELOC-style financing in small-cap biotech/health-tech, which can keep dilution overhang elevated for similarly structured issuers.
Limited, primarily affects Nasdaq small-cap sentiment rather than broad regional flows.
Low; this is company-specific financing mechanics with no cross-border deal terms disclosed.
Counterpoint
If the resale registration statement is already close to effectiveness, the market may price the dilution risk quickly and focus on the company’s ability to fund operations rather than the ELOC mechanics.
Key entities
- issuerGlucotrack, Inc.
Nasdaq-listed company amending its ELOC purchase agreement and committing to issue shares tied to resale registration effectiveness.
- investorWhite Lion Capital, LLC
Counterparty to the ELOC purchase agreement amendment, receiving commitment shares and potential true-up consideration.
